AI Article Synopsis
- * Biologics, especially IL-17 and IL-23 inhibitors, have been effective in treating psoriatic lesions, including challenging locations.
- * This case series presents the first real-life data showing the quick and successful treatment of facial psoriasis in six patients using bimekizumab, even though previous studies didn't specifically address facial lesions.
Article Abstract
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimekizumab in six patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11139169 | PMC |
| http://dx.doi.org/10.7573/dic.2024-1-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demographics, Disease Characteristics, and Treatment Patterns of Patients with Plaque Psoriasis Treated with Biological Drugs: The Experience of a Single-Centre Study in Poland.
J Clin Med
December 2024
Department of Dermatology and Venereology, Teaching Hospital No. 2, 90-549 Lodz, Poland.
: This study is a retrospective analysis of patients with plaque psoriasis treated with biological drugs at a single center in Poland. We sought to evaluate patient demographics, disease characteristics, comorbidity burden, and treatment patterns in this cohort. : Data were collected from the medical records of patients with plaque psoriasis who received biological treatments.
View Article and Find Full Text PDFObesity is a metabolic disease that is marked by excessive fat accumulation and is objectively defined as a body mass index (BMI) ≥30 kg/m2. Obesity is associated with several other comorbidities, including psoriasis, which is a chronic autoimmune skin disease. Adipocytes produce pro-inflammatory signaling molecules, namely adipokines and classic cytokines, that drive increased inflammation axnd may contribute to the pro-inflammatory pathways driving psoriasis disease pathogenesis.
View Article and Find Full Text PDFSingle-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.
Int J Dermatol
December 2024
1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study.
Arch Dermatol Res
December 2024
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napels, Italy.
Bimekizumab, is the most recent monoclonal antibody licensed for the management of moderate-to-severe plaque psoriasis, acting through the dual inhibition of interleukin (IL)-17 A and IL17F, setting it apart from other anti-IL17 biologics. To date, long-term data on the use of bimekizumab for the management of plaque psoriasis in a real-world setting are scant. The aim of our study was to evaluate the effectiveness and safety of bimekizumab in long-term.
View Article and Find Full Text PDFSwitching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.
Australas J Dermatol
December 2024
1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!